Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Notification of Drug Policy Revisions Effective January 1, 2025 (Posted November 1, 2024)
Medical Drug Policy NameRevised Criteria
Interleukin-5 Antagonists NotificationAdded requirement for trial and failure of the provider-administered formulations of Fasenra and Nucala prior to use of Cinqair within initial and continuation criteria. Adjusted maximum units for Cinqair according to FDA labeled dosing. Policy notification given 11/1/2024 for effective date 1/1/2025.
Ocular Angiogenesis Inhibitor Agents NotificationFor Beovu, added requirement for trial and failure of one of the following products: Eylea, Eylea HD, Lucentis, Byooviz, Cimerli, or Vabysmo. For Lucentis, removed requirement for trial and failure of Byooviz and Cimerli. Adjusted maximum units for Eylea, Lucentis, Byooviz, Cimerli, and Vabysmo for clarity according to FDA labeled dosing. Removed Macugen from policy due to market withdrawal and product discontinuation. Additional minor updates made to formatting throughout policy for clarity. Policy notification given 11/1/2024 for effective date 1/1/2025.
Tocilizumab (Actemra®) and Tocilizumab Biosimilars NotificationChanged requirement for trial and failure of a preferred tocilizumab biosimilar product to include Tyenne (tocilizumab-aazg) and adjusted non-preferred tocilizumab products to include Actemra (tocilizumab) and Tofidence (tocilizumab-bavi). Updated trial and failure criteria to also allow for presence of a documented serious adverse event requiring medical intervention from the preferred tocilizumab biosimilar product that is not anticipated with the requested non-preferred tocilizumab product, with required submission of an FDA MedWatch Adverse Event Reporting Form. Policy notification given 11/1/2024 for effective date 1/1/2025.